Insurer costs of COVID-19 by disease severity and duration

• Published in: The American journal of managed care Vol. 30; no. 3; pp. 124 - 129
• Main Authors: Holy, Chantal E, Patterson, Brandon J, Ruppenkamp, Jill W, Richards, Fayolah, Debnath, Ronita, El Khoury, Antoine C, DeMartino, Jessica K, Bookhart, Brahim, Coplan, Paul M
• Format: Journal Article
• Language: English
• Published: United States MultiMedia Healthcare Inc 01.03.2024
• Subjects: Asymptomatic; Codes; Comorbidity; Costs; COVID-19; Generalized linear models; Health care expenditures; Humans; Insurance Carriers; Patient Acuity; Patients; Respiratory diseases; Retrospective Studies; Severe acute respiratory syndrome coronavirus 2; Severity of Illness Index; United States > US
• ISSN: 1088-0224; 1936-2692; 1936-2692
• DOI: 10.37765/ajmc.2024.89513

To analyze US commercial insurance payments associated with COVID-19 as a function of severity and duration of disease. Retrospective database analysis. Patients with COVID-19 between April 1, 2020, and June 30, 2021, in the Merative MarketScan Commercial database were identified and stratified as having asymptomatic, mild, moderate (with and without lower respiratory disease), or severe/critical (S/C) disease based on the severity of the acute COVID-19 infection. Duration of disease (DOD) was estimated for all patients. Patients with DOD longer than 12 weeks were defined as having post-COVID-19 condition (PCC). Outcomes were all-cause payments (ACP) and disease-specific payments (DSP) for the entire DOD. Variables included demographic and comorbidities at the time of acute disease. Adjusted payments by disease severity were estimated using generalized linear models (γ distribution with log link). A total of 738,339 patients were included (374,401 asymptomatic, 156,220 mild, 180,213 moderate, and 27,505 S/C cases). DSP increased from $217 (95% CI, $214-221) for asymptomatic cases to $2744 (95% CI, $2678-$2811) for moderate cases with lower respiratory disease and $28,250 (95% CI, $26,963-$29,538) for S/C cases. ACP increased from $505 (95% CI, $497-$512) for asymptomatic cases to $46,538 (95% CI, $44,096-$48,979) for S/C cases. The DSP and ACP further increased by $50,736 (95% CI, $45,337-$56,136) and $94,839 (95% CI, $88,029-$101,649), respectively, in S/C cases with PCC vs a DOD of fewer than 4 weeks. COVID-19 payments for S/C cases were more than 10-fold greater than those of moderate cases and further increased by nearly $95,000 in S/C cases with PCC vs a DOD of fewer than 4 weeks.